Acute Toxicities of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Description

CAR T-cell therapy involves T-cells modified to target tumor cells through expression of a chimeric antigen receptor. While effective in controlling some tumors, they may have a number of toxicities.

Acute toxicities that have been observed:

(1) cytokine release syndrome (CRS), which rarely may develop into a fulminant macrophage activation syndrome (MAS)

(2) anaphylaxis or other allergic reaction

(3) on target/off tumor recognition

(4) CART-related encephalopathy syndrome (CRES)

where:

• CRES may involve confusion, delirium, aphasia, seizures, and/or raised intracranial pressure.

• MAS is also referred to as hemophagocytic lymphohistiocytosis (HLH).

To read more or access our algorithms and calculators, please log in or register.

Acute Toxicities of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Description

Specialty